ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

Rhea-AI Summary

ESSA Pharma Inc. (NASDAQ: EPIX) announced the results of its Annual General Meeting held on February 25, 2021. Shareholders re-elected the board of directors with significant majority support, including David R. Parkinson and Richard M. Glickman, among others. Key approvals included the re-appointment of Davidson & Company LLP as auditors, a new omnibus incentive plan, and amendments to the existing stock option plan. ESSA focuses on developing innovative therapies for prostate cancer, a significant medical area with rising treatment challenges.

Positive

• Shareholders re-elected board members with over 99% support.
• Approval of key governance measures enhances company structure.
• Focus on novel therapies for prostate cancer addresses unmet medical needs.

Negative

• Franklin M. Berger received only 84.33% of votes, indicating potential shareholder concerns.

HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").

At the Meeting, the shareholders of the Company (the "Shareholders") re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, and Ari Brettman to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
David R. Parkinson	18,880,503	99.97%	6,540	0.03%
Richard M. Glickman	18,817,052	99.63%	69,991	0.37%
Gary Sollis	18,815,800	99.62%	71,243	0.38%
Franklin M. Berger	15,928,283	84.33%	2,958,760	15.67%
Scott Requadt	18,863,013	99.87%	24,030	0.13%
Marella Thorell	18,880,723	99.97%	6,320	0.03%
Alex Martin	18,880,403	99.96%	6,640	0.04%
Sandy Zweifach	18,884,749	99.99%	2,294	0.01%
Ari Brettman	18,867,561	99.90%	19,482	0.10%

At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) the Company's omnibus incentive plan; (iii) an amendment to the Company's existing stock option plan (the "Amended Option Plan") and the previous grant of stock options exercisable thereunder; and (iv) an amendment to the Company's articles.

About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone can lead to mCRPC. The treatment of mCRPC patients has evolved rapidly over the past ten years. Despite these advances, many patients with mCRPC fail or develop resistance to existing treatments, leading to continued disease progression and limited survival rates.

View original content:http://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-and-special-meeting-of-shareholders-301236155.html

SOURCE ESSA Pharma Inc

FAQ

What were the results of the ESSA Pharma Inc. Annual General Meeting on February 25, 2021?

ESSA Pharma's Annual General Meeting resulted in the re-election of board members with significant support and the approval of several key governance measures.

What is the stock symbol for ESSA Pharma Inc.?

The stock symbol for ESSA Pharma Inc. is EPIX.

Who were the board members re-elected at ESSA Pharma's Annual General Meeting?

The re-elected board members include David R. Parkinson, Richard M. Glickman, and others.

What key approvals were made at ESSA Pharma's Annual General Meeting?

Key approvals included the re-appointment of auditors, a new omnibus incentive plan, and amendments to the stock option plan.

What is ESSA Pharma's focus area in the pharmaceutical industry?

ESSA Pharma focuses on developing novel therapies for the treatment of prostate cancer.